Tuesday, May 21, 2002

ASCO 2002 Dr. Heather Jones
Heather Jones, MD from the Department of Radiation at Abramson Cancer Center of the University of Pennsylvania presents her poster.


Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) porgressing on a same dose and schedule platinum-based regimen
Chemotherapy +/- whole-brain irradiation (WBI) for primary CNS lymphoma (PCNSL)-first experience with a randomized trial
Multicenter Phase III Trial to Compare Radical Nephrectomy Plus Adjuvant Autologous Tumor Cell-Lysate Vaccine Versus Radical Nephrectomy Without Adjuvant Treatment for Renal Cell Carcinoma Stages pT2-3bN0-3M0: a 3-year Analysis
p21 and p53 as prognostic factors for bladder preservation and survival in patients with bladder cancer treated with neoadjuvant chemotherapy
Preliminary results fo the GORTEC 96-01 randomized trail, comparing very accelerated radiotherapy versus concomitant radio-chemotherapy for locally inoperable HNSCC
Protective Effect Of Vitamin E (VE ) In Head And Neck Cancer Radiation Induced Mucositis: A Double-Blind Randomized Trial
Survival and Long-Term Toxicity Results in the SCOTROC Study: Docetaxel-Carboplatin (DC) vs. Paclitaxel-Carboplatin (PC) in Epithelial Ovarian Cancer (EOC)
Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer